Cabaletta Bio, Inc. (CABA): Capital Expenditures
$1.23M
Year ended 2025-12-31
$283.0K
Trailing 12 months to 2026-06-30
-20.6%
3-year compound annual growth
+14.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.23M | -44.4% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $2.21M | +221.8% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $687.0K | -72.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $2.45M | +110.4% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $1.17M | +83.6% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $635.0K | -8.4% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $693.0K | n/a | 2021-03-16, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $1.23M | -44.4% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $447.0K | -64.3% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $933.2K | +176.7% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $1.36M | -72.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $13.4K | n/a |
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | $618.0K | -39.7% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $31.0K | -98.8% |
Compare CABA, AURA, SABS, CGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗